Quince raises $11.5M in private placement of stock and warrants; management participates

Quince Therapeutics, Inc.

Sold 6,671,928 shares, 2M pre-funded warrants, and 8,671,928 common warrants for $11.5M gross proceeds.
Common warrants exercisable at $1.20/share for 5 years; pre-funded warrants exercisable at $0.001/share.
Management investors: CEO Dirk Thye ($200k), COO Brendan Hannah ($50k), President Charles Ryan ($10k).
Company to file resale registration statement within 120 days under Registration Rights Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.